Four years on, GSK has agreed to pay $13bn (€10.5bn) to buyout Novartis’s 36.5% stake in the venture, allowing the Swiss pharma giant to concentrate on its core business.

https://www.in-pharmatechnologist.com/Article/2018/03/27/Novartis-Time-is-right-for-13bn-consumer-health-sale-to-GSK?utm_source=newsletter_daily&utm_medium=email&utm_campaign=27-Mar-2018&c=B5LaTvdHM6Cus9hGIJ8ziL1sqCittSVY&p2=